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OBJECTIVES We sought to conduct a randomized trial with folic acid 0.5 mg/day in a patient population
with stable coronary artery disease (CAD).
BACKGROUND Folic acid has favorable effects on vascular endothelium and lowers plasma homocysteine
levels. In addition, homocysteine appears to be an independent risk factor for atherosclerotic
disease. However, the value of folic acid in secondary prevention had seldom been tested.
METHODS In this open-label study, 593 patients were included; 300 were randomized to folic acid and
293 served as controls. Mean follow-up time was 24 months. At baseline all patients had been
on statin therapy for a mean of 3.2 years.
RESULTS In patients treated with folic acid, plasma homocysteine levels decreased by 18%, from 12.0
 4.8 to 9.4  3.5 mol/l, whereas these levels remained unaffected in the control group (p
 0.001 between groups). The primary end point (all-cause mortality and a composite of
vascular events) was encountered in 31 (10.3%) patients in the folic acid group and in 28
(9.6%) patients in the control group (relative risk 1.05; 95% confidence interval: 0.63 to 1.75).
In a multifactorial survival model with adjustments for clinical factors, the most predictive
laboratory parameters were, in order of significance, levels of creatinine clearance, plasma
fibrinogen, and homocysteine.
CONCLUSIONS Within two years, folic acid does not seem to reduce clinical end points in patients with stable
coronary artery disease (CAD) while on statin treatment. Homocysteine might therefore
merely be a modifiable marker of disease. Thus, low-dose folic acid supplementation should
be treated with reservation, until more trial outcomes become available. (J Am Coll Cardiol
2003;41:2105–13) © 2003 by the American College of Cardiology Foundation
In patients with coronary artery disease (CAD), homocys-
teine has been described as an independent predictor of
mortality (1–4). A mild to moderate elevation of homocys-
teine is common and is strongly related to folate status (5).
Nevertheless, the exact mechanism of the deleterious effects
of homocysteine on the progression of atherosclerotic dis-
ease is still unknown. It has been suggested that it involves
endothelial damage, increased adhesiveness of platelets, and
disturbance of the clotting cascade (6).
Simple and inexpensive therapy with folic acid reduces
plasma homocysteine levels and normalizes endothelial
function (7,8). Folic acid dose as low as 0.5 mg/day is
sufficient to effectively lower plasma homocysteine level (9).
Moreover, it has also been demonstrated that normalization
of endothelial function by folic acid appears to be indepen-
dent of its effect on homocysteine (10). In addition, one
clinical trial with folic acid-containing multivitamins has
shown to prevent restenosis following percutaneous coro-
nary intervention (PCI) (11). Yet, up till now, the folic acid
hypothesis has not been tested in a population with stable
atherosclerotic disease with hard clinical end points such as
cardiovascular mortality or morbidity.
METHODS
Patients. Patients with stable CAD were screened for
inclusion. Patient history had to include one of the follow-
ing: myocardial infarction (MI), significant coronary artery
lesions (60%) on coronary angiography, PCI, and/or
coronary artery bypass graft surgery (CABG). Patients had
to be stable, with no invasive vascular procedures scheduled.
Patients were eligible when they were on statin therapy for
at least three months. Patients taking any form of vitamin
B-containing medication, regularly or sporadic, were con-
sidered eligible for this study.
Main exclusion criteria were age below 18 years, history
of low vitamin B12 level, treatment for hyperhomocysteine-
mia, severe renal failure, or any other treatment for renal
disease, known hepatic disease, signs and symptoms of
severe heart failure (New York Heart Association functional
class IV) or any other serious illness that would exclude
follow-up time of at least three years.
Study treatment and assessments. For the study, consec-
utive patients visiting the outpatient department of the
cardiology department were screened. As soon as eligibility
was confirmed, patients were invited to participate in the
study. Written informed consent was obtained. A computer
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program randomly allocated patients either to treatment
with open-label folic acid 0.5 mg/day or to standard care.
Standard care implied the same intensive follow-up and
treatment of risk factors. A nurse counselled all patients. In
all patients, dosage of statins was increased when necessary.
At least one of four goals was meticulously pursued: first, a
decrement of low-density lipoprotein cholesterol (LDL-C)
of 30% (compared to values before the initiation of statin
treatment); second, an LDL-C value of 3 mmol/l; third,
an apolipoprotein-B (apoB) value of 1 g/l; and fourth, a
decrement of apoB values of 30% compared to prestatin
values. During the trial, patients were encouraged to imple-
ment and continue dietary measures. Persistent nicotine use
was discouraged at regular intervals. Patients were followed
for a maximum of 36 months. During the entire study,
clinical events were carefully registered. Visits for laboratory
examinations were planned at 3, 6, 12, 24, and 36 months,
and patients were encouraged to contact by telephone in
order to be informed about their cholesterol status. Annual
visits with the nurse were scheduled.
The study was conducted in accordance with the Decla-
ration of Helsinki as revised in 1996, and it was performed
in a rural area in the vicinity of the city of Goes, called the
Bevelanden (province of Zeeland, the Netherlands), from
November 1998 to January 2002. The local ethics commit-
tee approved the study protocol prior to the start of the trial.
Laboratory procedures. Blood samples were taken in the
morning after an overnight fast. All analyses were done in
the same hospital laboratory. Total serum cholesterol (TC)
and triglyceride concentrations were measured enzymati-
cally (Vitros analyzer, Johnson & Johnson). High-density
lipoprotein-cholesterol (HDL-C) fractions were prepared
by precipitation from serum of apoB-containing lipopro-
teins with the use of dextran sulfate and MgCl2 (magnesium
chloride). Serum LDL-C was calculated using the Friede-
wald formula (Friedewald, Clin Chem 1972). Apolipopro-
tein A-I (apoA-I) and apoB were determined by immuno-
nephelometry on a Beckman array system. Beckman
reagents, calibrators, and standards were used. From April
2000, high-selective C-reactive protein (HS-CRP) mea-
surements were done with particle-enhanced turbidimetric
immunoassay technique, which provided a sensitivity of 0.5
mg/l and represented the lowest concentration of CRP that
could be distinguished from zero (Dade Behring Dimension
Chemical Chemistry System). Plasma fibrinogen levels were
determined using the IL-test PT-fibrinogen recombinant
method (ACL Futura).
Creatinine clearance was estimated by the Cockroft-
Gault equation (12). Total homocysteine level was mea-
sured in plasma with a fluorescence polarization immuno-
assay on an Imx analyzer. Imx reagents and calibrators were
used (Abbott). As synthesis of homocysteine continued in
red blood cells after drawing, samples were centrifuged
immediately and put on ice. Afterwards, measurements
were done within a few hours. Serum folate level was
measured with an ion capture assay (Imx) using monoclonal
antibodies and was expressed as nmol/l. As recent food
intake could influence folate levels, the specimens were
taken in a fasting state as well. Special care was taken not to
hemolyze the samples, as red-blood-cell-containing samples
can give falsely elevated folate levels. Vitamin B12 was
measured with an Imx B12 assay based on microparticle
enzyme immunoessay technology (Abbott).
Study end points. The primary end point was a composite
of vascular events. These events were defined as vascular
death (sudden death, fatal recurrent MI, fatal stroke, and
other cardiovascular deaths), noncardiovascular death, re-
current MI, or invasive coronary procedures (PCI, CABG),
cerebrovascular accident (CVA), or transient ischemic at-
tack (TIA), or any other vascular surgery such as carotid
endarterectomy, abdominal aneurysmectomy, or peripheral
vascular surgery including limb amputation for vascular
reasons. Myocardial infarction was defined according to
previously used criteria; two out of three criteria should be
positive: chest pain lasting 30 min, creatine kinase eleva-
tion2 times the upper limit of normal or new pathological
Q waves of0.04-s duration or25% of the corresponding
R-wave amplitude, both in at least two contiguous leads.
The decision to proceed to any coronary vascular procedures
such as PCI or CABG was made in other hospitals without
knowledge of folic acid substitution. Hospitalization due to
increasing anginal complaints with or without troponin
elevation, which was determined as “unstable angina pecto-
ris,” was recorded but was not considered as a part of the
primary end point in this study. Adjudication of all clinical
events was performed by an independent end point moni-
toring committee unaware of treatment arm.
Statistical analysis. All randomized patients fulfilling the
eligibility criteria were included in the analysis of time to a
major clinical event according to intention-to-treat princi-
ple. Continuous data were presented as mean and SD.
Continuous data were compared in the two treatment
groups using unpaired t tests. Categorical data were pre-
sented by percentage and count of each category. Treatment
comparisons were made using the Fisher exact test or
chi-squared test. For correlations, bivariate correlation co-
efficient was calculated with the Spearman rank. Time-to-
event were presented as Kaplan-Meier survival curves and
were compared using log-rank tests. For covariate analysis,
Abbreviations and Acronyms
CABG  coronary artery bypass graft
CAD  coronary artery disease
CVA  cerebrovascular accident
HDL-C  high-density lipoprotein-cholesterol
HS-CRP  high-selective C-reactive protein
LDL-C  low-density lipoprotein-cholesterol
MI  myocardial infarction
PCI  percutaneous coronary intervention
RR  relative risk
TC  total serum cholesterol
TIA  transient ischemic attack
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the Cox regression analysis was used. The study was
powered for a 50% reduction in clinical events on the basis
of existing observational data in populations with CAD
(1–3). We assumed that the two-year event rate was about
15%. In order to obtain 80% power (5% significance level) to
detect a relative risk (RR) of 0.5, we included 300 patients
in each treatment group. Analyses were performed using
commercially available computer software (SPSS).
RESULTS
Baseline. From November 1998 to September 2001, a total
of 593 patients were included in this study. Of these
patients, 300 were randomly assigned to folic acid 0.5
mg/day, and 293 patients served as a control group. Twenty
eligible patients did not want to participate in the study
mainly because of insufficient transport facilities in our rural
area. Mean follow-up time was 24  10 months. Baseline
characteristics are depicted in Table 1. Manifestations of
CAD such as previous MI, PCI, or CABG were evenly
distributed between both groups as were other concomitant
vascular diseases, such as CVA or TIA or peripheral
vascular disease.
Lipid parameters. Mean TC value before treatment was
6.8 mmol/l; mean LDL-C, 4.7 mmol/l; mean HDL-C, 1.1
mmol/l; mean apoA-1, 1.3 g/l; and mean apoB, 1.4 g/l.
Laboratory results at baseline are shown in Table 1. As most
patients were already on statin therapy for more than three
years, the TC level at inclusion was already well below 5
mmol/l in the majority of patients. During follow-up the
mean TC and LDL-C values did not change (data not
shown). In both groups, statin treatment was intensified
when necessary.
Homocysteine, folic acid, vitamin B12, and creatinine
clearance. At baseline, in both groups 15% to 16% of
patients used vitamin B-containing medication, sometimes
regularly and sometimes only in winter months (Table 1).
Most vitamin B users mentioned use of a complex form of
vitamin B, which contained both folic acid and pyridoxine.
During the study, patients were neither encouraged nor
discouraged to continue these vitamin supplements. As
stated before, for reason of extrinsic validity, patients using
vitamin supplementation on their own initiative were con-
sidered eligible for this study. Patients using vitamin
B-containing supplements had a higher level of serum folate
(19.4  8.2 vs. 15.4  5.5 nmol/l, p  0.001) and lower
level of plasma homocysteine (11.0  3.8 vs. 12.3  4.3
mol/l, p  0.015) compared to patients who did not use
these supplements. During the study no significant drop-in
of nonstudy folic acid in the control group was encountered
as plasma folic acid and homocysteine levels in this group
remained unaltered (data not shown).
Folate status at inclusion was unrelated to the age of the
Table 1. Baseline Characteristics of 593 Patients Randomly Assigned to Folic Acid (n  300) or
Controls (n  293)
Patient Characteristic Folic Acid Control p Value
Age (yrs) 64.9  9.9 65.5  9.7 0.42
Male gender (%) 76 80 0.17
BMI (kg/m2) 26.7  3.4 27.3  3.6 0.026
History of
MI (%) 59 53 0.08
PCI and/or CABG (%) 58 65 0.06
TIA and/or CVA (%) 6 7 0.45
Peripheral vascular disease (%) 8 9 0.41
Diabetes (%) 7 11 0.09
Use of vitamin B-containing tablets (%) 15 16 0.61
Persistent nicotine use (%) 15 16 0.46
Use of lipid-lowering therapy before randomization (yrs) 3.2  2.4 3.3  2.3 0.55
Mean follow-up time (months) 24.2  10.9 23.2  10.1 0.23
Laboratory Parameters
At inclusion
Total cholesterol (mmol/l) 4.7  0.8 4.5  0.7 0.002
LDL-C (mmol/l) 2.7  0.7 2.6  0.6 0.006
HDL-C (mmol/l) 1.12  0.33 1.14  0.30 0.96
Triglycerides (mmol/l) 1.8  0.91 1.8  0.96 0.88
ApoA1 (g/l) 1.35  0.20 1.31  0.20 0.054
ApoB (g/l) 0.93  0.20 0.91  0.18 0.11
Vitamin B12 (pmol/l) 286  129 294  162 0.51
Homocysteine (mol/l) 12.0  4.8 12.2  3.8 0.67
Folate (nmol/l) 17  7 15  5 0.001
Creatinine clearance (ml/min) 78  26 77  24 0.80
Fibrinogen (g/l) 3.98  0.87 4.01  0.82 0.63
BMI  body mass index; CABG  coronary artery bypass graft; CVA  cerebrovascular accident; HDL-C  high-density
lipoprotein; LDL-C low-density lipoprotein; MImyocardial infarction; PCI percutaneous coronary interception; TIA
transient ischemic attack.
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patients. However, vitamin B12 level decreased with age (r
 0.87, p  0.035). After correction for age and gender,
the strongest predictors of plasma homocysteine level were
levels of serum folate (r  0.31, p  0.001), vitamin B12
level (r  0.22, p  0.001) and creatinine clearance (r 
0.21, p  0.001). In the folic acid-treated group, plasma
homocysteine level at three months’ follow-up decreased,
with 18% going from 12.0  4.8 to 9.4  3.5 mol/l (p 
0.001), and serum folate levels increased from 17  7 to 33
 6 nmol/l (p  0.001). These values persisted at six
months’ follow-up and did not change significantly. The
decrement of plasma homocysteine was dependent on base-
line values. In the lowest quartile, the percentage decrement
was 9.6%, and in the third and fourth quartile this percent-
age increased up to 21% and 28%, respectively.
A total of 21 patients with asymptomatically low vitamin
B12 levels (120 pmol/l) were encountered: 11 patients in
the folic acid-treated group and 10 control patients. When
repeated measurements showed persistence of low vitamin
B12 levels, the general physician was given the advice to
substitute cyanocobalamine i.m. Substitution occurred in 7
patients in both groups (14 total).
Homocysteine level at baseline was correlated with the
log linear of serum folate with r  0.405 (p  0.001) and
of vitamin B12 with r  0.249 (p  0.001). After six
months of treatment the relation of homocysteine level with
serum folate was not significant anymore, but the correla-
tion with vitamin B12 persisted (r  0.204, p  0.004).
Fibrinogen and HS-CRP. During follow-up, fibrinogen
as well as HS-CRP levels in both groups did not change
significantly. The HS-CRP measurements were only per-
formed in 158 cases included after April 2000 and were
therefore excluded from the overall analysis. Yet, in cases
where the data were available, HS-CRP levels were related
to fibrinogen levels.
Clinical events and other follow-up data. After inclusion,
24 patients withdrew from the study (12 in each group), but
were followed according to the protocol and were included
in the analysis on an intention-to-treat basis. No patients
were lost to follow-up.
Clinical cardiovascular events were evenly distributed in
both treatment arms. In total, 37 (12.3%) clinical events in
the folic acid group and 33 (11.2%) in the control group
were observed, in 31 (10.3%) and 28 (9.6%) patients,
respectively (Table 2). The time to the first clinical event is
depicted in the Kaplan-Meier curve in Figure 1. No
statistically significant difference existed between both
groups (log-rank test, p 0.85). This was also found for the
patients in the highest quartile of plasma homocysteine
(13.7 mol/l) (log-rank test, p  0.86) (Fig. 1). Hospi-
talization for other reasons (which was not a part of the
composite end point) was seen 95 (31.7%) times in the
folic-acid group and 66 (22.5%) times in the control group
and were mainly due to cataract or orthopedic surgery in this
relative elderly population. Unstable angina or what we
nowadays consider as non–ST-elevation acute coronary
syndrome (which was also not a part of the primary end
point) was evenly distributed between both groups (11 cases
in each group).
Survival analysis. Because no effect of folic acid interven-
tion was observed, further analyses were done considering
the study group as a whole. Four clinical parameters were
dominant: age, history of diabetes, concomitant peripheral-
vascular, and cerebrovascular disease. Three laboratory pa-
rameters were significant risk factors: calculated creatinine
clearance, fibrinogen, and homocysteine. None of the on-
treatment lipid values including apoA and apoB were found
to be predictive.
Top-risk quartile analyses for the respective parameters,
corrected for diabetes, gender, prior MI, PCI, and CABG,
are depicted in Table 3. The respective Kaplan-Meier curves
are shown in Figure 2. Nevertheless, in a multivariate
model, corrected for the above-mentioned five clinical
parameters, homocysteine and fibrinogen levels disappeared
as significant risk factors when creatinine clearance level was
introduced.
DISCUSSION
In this study, treatment with folic acid did not result in
reduction of recurrence of cardiovascular events. The study
was performed with the hypothesis that folic acid could have
an additive effect in secondary prevention. This hypothesis
was tested in a relatively high-risk population of patients
with stable CAD with already optimally regulated lipid
levels in addition to other well-known secondary prevention
measures. At entry, most patients had already been on statin
therapy for more than three years. The risk reduction thus
pursued may have overshadowed the potential beneficial
effects of folic acid on progression of atherosclerosis.
This study was designed on the basis of previous epide-
miological evidence. In the past, much enthusiasm has been
provoked by mostly cross-sectional and case-control studies
(1–6,13–16), though with time, most prospective studies
indicated less or absent association between homocysteine
levels and cardiovascular risk. Therefore, it is reasonable to
examine different meta-analyses of prospective studies that
Table 2. Cardiovascular Mortality and Morbidity
Folic Acid Control
Death (due to any reason) 12 14
Cardiovascular death 7 9
Noncardiovascular death 5 5
MI 3 4
PCI 6 3
CABG 4 3
CVA/TIA 4 3
Other vascular surgery 9 6
Death and/or any cardiovascular event 37 33
As per clinical event category, the number of patients with at least one event is
presented. No double counting of patients for multiple events within a category was
performed. Between categories, patients are double-counted in case of multiple events
(e.g., a patient suffering two recurrent myocardial infarctions followed by a CABG is
counted once in both categories).
Abbreviations as in Table 1.
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Figure 1. Cumulative event rate according to randomization to folic acid treatment (solid line) and control (dashed line). (A) Analysis for the entire group
and (B) for patients with the highest quartile (Q-4) for baseline plasma homocysteine level ( 13.7 mol/l). Probability value by log-rank statistic.
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have recently been published. One of those meta-analyses
suggests that the odds ratio (OR) for ischemic heart disease
for a 5 mol/l increase in serum homocysteine was 1.32
(95% confidence interval [CI] 1.19 to 1.45) (15). Another
meta-analysis suggests that a decrease in homocysteine level
of about 3 mol/l was associated with an 11% (OR 0.89;
95% CI 0.83 to 0.96) lower risk of ischemic heart disease
and 19% (OR 0.81, 95% CI 0.69 to 0.95) lower stroke risk
in healthy populations (16). It is important to note that
most of the studies considered in the meta-analyses primar-
ily included those performed in previously healthy popula-
tions so as to avoid confounding by disease. Only a few
studies concern a prospective observation of mortality in
patients with CAD (1–4).
In the observational study of Nygard et al. (2) a wide
dose-response relation was observed within the range of
homocysteine values, from about 5 mol/l to more than 20
mol/l. The investigators calculated an adjusted mortality
ratio of 1.9 for patients with total homocysteine levels
between 9.0 and 14.9 mol/l as compared to those with
values below 9 mol/l. In our study, at six months, mean
homocysteine levels were 12.2  3.8 mol/l in the control
group and 9.4  3.7 mol/l in the folic acid-treated group,
respectively. Consequently, on the basis of these figures one
can expect to find a RR of about 0.5 (1/1.9) with folic acid
intervention in patients with stable CAD.
Moreover, in another case-control study (3) the RR
among men with known heart disease at baseline was, after
adjustment for known risk factors, 2.23 (95% CI 1.03 to
4.85) in the highest serum homocysteine quintile compared
with the lowest; yet the corresponding RR was only 0.90
(95% CI 0.51 to 1.60) among the men free of heart disease
at baseline. This finding could indicate that the prognostic
role of homocysteine is more pronounced in populations
with existing heart disease compared to initially healthy
populations.
Indeed, in our study it could be confirmed that plasma
homocysteine levels at entry correlated with the risk of
recurrent events, yet we did not observe decrement of risk
with reduction of plasma homocysteine with folic acid, even
when we only considered patients with the highest quartile
of plasma homocysteine.
What are the existing data concerning folic acid inter-
vention in coronary heart disease in terms of hard clinical
end points? One recent study concerns a population under-
going PCI (11). A combination treatment of folic acid,
vitamin B12, and pyridoxine decreases the rate of restenosis
and the need for revascularization. Nonetheless, no differ-
ence was observed in the rate of death from cardiac causes or
nonfatal MI. Because of intervention of a vitamin combi-
nation, the decrement of homocysteine in this study was
more pronounced, from 11.1  4.3 to 7.2  2.4 mol/l.
Another placebo-controlled intervention with folic acid 5
mg/day in a population with ischemic heart disease was
recently presented (17). The study was performed in a
comparable population as our study, with 1,882 patients
observed for a median of 1.7 years. Treatment reduced
homocysteine level from 11.2  6.9 mol/l to 9.7  5.3
mol/l, which is largely comparable to our observation.
However, this study also did not observe reduction in risk in
composite end point consisting of nonfatal MI, cardiovas-
cular death, or unplanned revascularization (RR 0.97, 95%
CI 0.72 to 1.29). Thus, these results are highly comparable
to our own observations.
One potential limitation of our study concerns the inclu-
sion of patients already using vitamin B-containing supple-
ments on their own initiative. This is done on purpose for
extrinsic validity reasons as it is well appreciated that a
substantial proportion of the population uses the medication
on a (semi)regular basis; in our study the percentage of users
was about 15%. Yet when we dismissed these patients in the
overall analysis, the results remained more or less unaltered.
One limitation other ongoing studies might encounter
elsewhere is the folic acid food fortification program. How-
ever, in the Netherlands this program was not introduced
until fairly recently.
Other observations in this study are worth mentioning. In
accord with the published data, in our study it was observed
that homocysteine levels are related to age, folate status, and
vitamin B12 levels (18). In addition, it could be confirmed
that the amount of reduction of plasma homocysteine is
dependent on homocysteine level at baseline; the higher the
baseline of homocysteine, the more reduction can be
achieved. This reduction can be up to 28% in the highest
quartile of plasma homocysteine. Yet this phenomenon
could also be explained by the regression to the mean.
Furthermore, we observed that, while patients are on folic
acid treatment, homocysteine is no longer related to the
height of serum folate, but that relations of homocysteine
with vitamin B12 levels persist. Thus, if higher homocys-
teine reduction is pursued—for instance, with food fortifi-
cation—it is probably favorable not only to supplement folic
acid but also vitamin B12. This observation is a confirmation
of a recent suggestion (19).
The matter of causality of homocysteine in atherosclerosis
remains a highly debatable issue. Although we and others
observed a relation between homocysteine level at entry of
the study and prognosis, other laboratory parameters seem
Table 3. Contribution of Fibrinogen, Creatinine Clearance, and
Homocysteine to the Survival Model
Factor RR* 95% CI
p
Value
Creatinine clearance 2.13 1.23–3.69 0.007
Fibrinogen 2.10 1.23–3.56 0.007
Homocysteine 1.96 1.15–3.33 0.014
The survival model includes adjustment for diabetes, gender, prior myocardial
infarction, percutaneous coronary intervention, and coronary artery bypass graft. *The
relative risk of experiencing an event per unit time for patients in the top-risk quartile
(Q4 for fibrinogen and homocysteine; Q1 for creatinine clearance) to patients in the
lower three risk quartiles (Q1–3 for fibrinogen and homocysteine, Q2–4 for creatinine
clearance) of the specified factor. The top-risk quartiles were 5 g/l for fibrinogen,
13.7 mol/l for homocysteine, and 60 ml/min for creatinine clearance.
CI  confidence interval; RR  relative risk.
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Figure 2. Cumulative rate of first cardiovascular event for two markers. Kaplan-Meier cumulative event rates for top-risk quartile (dashed line) versus lower
three risk quartiles (solid line) are shown for fibrinogen (A) and homocysteine (B). The Q-4 is top-risk quartile for fibrinogen ( 5 g/l) and homocysteine
( 13.7 mol/l). Value by log-rank statistic.
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to be more prominent. One of these parameters is creatinine
clearance. In most observational studies concerning homo-
cysteine, only creatinine level was measured. We are more
comfortable with calculated creatinine clearance as a mea-
sure of renal function. As it turns out, we observed a strong
relation of creatinine clearance with recurrent events as renal
function probably reflects the extent of cardiovascular dis-
ease. In addition, renal function plays a key role in the
metabolism of homocysteine. Thus, it is conceivable that,
among others, homocysteine is also a marker of renal
function and that modulating this marker does not influence
cardiovascular prognosis.
Another marker with a well-known prognostic character-
istic is fibrinogen (20,21). In addition, fibrinogen is an
independent predictor for subsequent acute coronary syn-
dromes in patients with stable angina (22). Moreover,
fibrinogen not only seems to be linked to thrombosis, but
also to inflammation (23). Nowadays, both phenomena are
considered highly relevant in the mechanism of disease of
atherosclerosis (24). In our study we could confirm the
relation between fibrinogen levels and subsequent events.
Overall, in a multifactorial survival model with adjustments
for clinical factors, the most predictive laboratory parame-
ters in our study were, in order of significance, creatinine
clearance, plasma fibrinogen, and homocysteine.
Study limitations. The current open-label study was pow-
ered for a 50% reduction of the event-rate under folic acid
on the basis of observational studies in patients with
established CAD (1–4). However, in a recent meta-analysis
(yet predominantly including studies of patients without
preexisting vascular disease) it was calculated that lowering
homocysteine by 3 mmol/l from current levels reduces the
risk of ischemic heart disease by 16% (11% to 20%) (15). Of
course, our study is underpowered to see such a relatively
small effect. In our investigation (with 2.6 mol/l lowering
of mean plasma homocysteine) the event rates at 24 months
were 9.2% and 9.7% in the placebo and folic acid groups,
respectively. The 95% CI of RR of folic acid treatment
ranged from 0.63 to 1.75, meaning that we cannot exclude
a positive effect of folic acid treatment as great as 37% on
risk reduction. Additionally, the time frame of two years
necessary to see any effect may be of importance. Neverthe-
less, it is fair to say that one cannot expect major risk-
reduction with folic acid substitution in the setting of
secondary prevention within the time frame of two years.
This is in agreement with recent findings (17). Nevertheless,
we should not overinterpret the results of our study, as a lack
of evidence is not the same as an evidence of lack of effect.
We therefore have to await the results of ongoing trials in
larger populations and with a longer follow-up time, such as
the NORVIT, VITATOPS, and SEARCH trials, before
one can support the routine use of folic acid supplementa-
tion in patients with ischemic heart disease.
Conclusions. In conclusion, low-dose folic acid in addition
to statin therapy does not seem to affect the progress of
cardiovascular disease within two years in terms of hard
clinical end points in patients with stable CAD. Homocys-
teine level is tightly linked to creatinine clearance. In
addition, creatinine clearance can be interpreted as a mirror
of the extent of atherosclerotic disease. Thus, homocysteine
levels might, among others, be a marker of atherosclerotic
disease. This study therefore does not seem to support the
routine use of folic acid in patients with stable CAD.
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